SLC5A5 and neoplasm: Furthermore, the ability of EGFR-targeted nanoparticles to target NIS to ATC was demonstrated in vivo by xenograft mice treated with an application of LPEI-PEG-GE11/NIS and 131I. Compared to control groups, these mice showed a significant delay in tumor growth and an increase in survival time.